Non-coding RNAs and EZH2 interactions in cancer: Long and short tales from the transcriptome

International Journal of Cancer

Volumn 133, Issue 2, 2013, Pages 267-274

  Benetatos, Leonidas ^a   Voulgaris, Evangelos ^b   Vartholomatos, George ^c   Hatzimichael, Eleftheria ^c,d  

^a General Hospital of Preveza   (Greece)

^b 217 Military Hospital of Ioannina   (Greece)

^c UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^d UNIVERSITY OF IOANNINA   (Greece)

Author keywords

cancer; chromatin modifications; EZH2; lncRNAs; microRNAs

Indexed keywords

LONG UNTRANSLATED RNA; MICRORNA; POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTOME; UNTRANSLATED RNA;

BREAST CANCER; CARCINOGENESIS; CHROMOSOME CONDENSATION; CPG ISLAND; DNA MODIFICATION; DNA REPAIR; DNA REPLICATION; EPIGENETICS; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENOME; GLIOBLASTOMA; HISTONE MODIFICATION; HUMAN; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT TRANSFORMATION; NEOPLASM; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN INTERACTION; REVIEW; STOMACH CANCER; TRANSITIONAL CELL CARCINOMA;

ANIMALS; CHROMATIN; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM METASTASIS; NEOPLASMS; POLYCOMB REPRESSIVE COMPLEX 2; RNA, LONG UNTRANSLATED; TRANSCRIPTION, GENETIC; TRANSCRIPTOME;

EID: 84877807808     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27859     Document Type: Review

References (93)

1. Kim JK, Samaranayake M, Pradhan S,. Epigenetic mechanisms in mammals. Cell Mol Life Sci 2009; 66: 596-612.
2. Kouzarides T,. Chromatin modifications and their function. Cell 2007; 128: 693-705.
3. Portela A, Esteller M,. Epigenetic modifications and human disease. Nat Biotechnol 2010; 28: 1057-68.
4. Meissner A,. Epigenetic modifications in pluripotent and differentiated cells. Nat Biotechnol 2010; 28: 1079-88.
5. Deaton AM, Bird A,. CpG islands and the regulation of transcription. Genes Dev 2011; 25: 1010-22.
6. Esteller M,. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007; 8: 286-98.
7. Kelly TK, De Carvalho DD, Jones PA,. Epigenetic modifications as therapeutic targets. Nat Biotechnol 2010; 28: 1069-78.
8. Berdasco M, Esteller M,. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell 2010; 19: 698-711.
9. Bantignies F, Cavalli G,. Polycomb group proteins: repression in 3D. Trends Genet 2011; 27: 454-64.
10. Crea F, Duhagon Serrat MA, Hurt EM, et al. BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer. Int J Cancer 2011; 128: 1946-54.
11. Kemp CD, Rao M, Xi S, et al. Polycomb repressor complex-2 is a novel target for mesothelioma therapy. Clin Cancer Res 2012; 18: 77-90.
12. Bracken AP, Helin K,. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer 2009; 9: 773-84.
13. Margueron R, Reinberg D,. The Polycomb complex PRC2 and its mark in life. Nature 2011; 469: 343-349.
14. Ho L, Crabtree GR,. An EZ mark to miss. Cell Stem Cell 2008; 3: 577-8.
15. Chou RH, Yu YL, Hung MC,. The roles of EZH2 in cell lineage commitment. Am J Transl Res 2011; 3: 243-50.
16. Tsang DP, Cheng AS,. Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. J Gastroenterol Hepatol 2011; 26: 19-27.
17. Crea F,. EZH2 and cancer stem cells: fact or fiction? Epigenomics 2011; 3: 127-8.
18. Chang CJ, Hung MC,. The role of EZH2 in tumour progression. Br J Cancer 2012; 106: 243-7.
19. Herrera-Merchan A, Arranz L, Ligos JM, et al. Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. Nat Commun 2012; 3: 623.
20. Ryan RJ, Nitta M, Borger D, et al. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLoS One 2011; 6: e28585.
21. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010; 42: 722-6.
22. Nikoloski G, Langemeijer SM, Kuiper RP, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010; 42: 665-7.
23. Ntziachristos P, Tsirigos A, Vlierberghe PV, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 2012; 18: 298-303.
24. Kim VN, Han J, Siomi MC,. Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009; 10: 126-39.
25. Yang JS, Lai EC,. Alternative miRNA biogenesis pathways and the interpretation of core miRNA pathway mutants. Mol Cell 2011; 43; 892-903.
26. Calin GA, Croce CM,. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-66.
27. Benetatos L, Vartholomatos G,. Deregulated microRNAs in multiple myeloma. Cancer 2012; 118: 878-87.
28. Marcucci G, Mrõzek K, Radmacher MD, et al. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 2011; 117: 1121-29.
29. Schotte D, Pieters R, Den Boer ML,. MicroRNAs in acute leukemia: from biological players to clinical contributors. Leukemia 2012; 26: 1-12.
30. Guil S, Esteller M,. DNA methylomes, histone codes and miRNAs: tying it all together. Int J Biochem Cell Biol 2009; 41: 87-95.
31. Hatziapostolou M, Iliopoulos D,. Epigenetic aberrations during oncogenesis. Cell Mol Life Sci 2011; 68: 1681-702.
32. Varambally S, Cao Q, Mani RS, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008; 322: 1695-99.
33. Gandellini P, Folini M, Longoni N, et al. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res 2009; 69: 2287-95.
34. Cao P, Deng Z, Wan M, et al. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer 2010; 9: 108.
35. Tzatsos A, Paskaleva P, Lymperi S, et al. Lysine-specific demethylase 2B (KDM2B)-let-7-enhancer of zester homolog 2 (EZH2) pathway regulates cell cycle progression and senescence in primary cells. J Biol Chem 2011; 286: 33061-9.
36. Kong D, Heath E, Chen W, et al. Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS One 2012; 7: e33729.
37. Kottakis F, Polytarchou C, Foltopoulou P, et al. FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway. Mol Cell 2011; 43: 285-98.
38. Banerjee R, Mani RS, Russo N, et al. The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. Oncogene 2011; 30: 4339-49.
39. Liu X, Wang C, Chen Z, et al. MicroRNA-138 suppresses epithelial-mesenchymal transition in squamous cell carcinoma cell lines. Biochem J 2011; 440: 23-31.
40. Carvalho J, van Grieken NC, Pereira PM, et al. Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. J Pathol. 2012; 228: 31-44.
41. 1). Pharm Res 2011; 28: 3079-90.
42. Chiang CW, Huang Y, Leong KW, et al. PKCalpha mediated induction of miR-101 in human hepatoma HepG2 cells. J Biomed Sci 2010; 17: 35.
43. Zhang JG, Guo JF, Liu DL, et al. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J Thorac Oncol 2011; 6: 671-8.
44. Wang HJ, Ruan HJ, He XJ, et al. MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer 2010; 46: 2295-303.
45. Nakahara O, Takamori H, Iwatsuki M, et al. Carcinogenesis of intraductal papillary mucinous neoplasm of the pancreas: loss of microRNA-101 promotes overexpression of histone methyltransferase EZH2. Ann Surg Oncol 2012; 19 (Suppl 3): S565-71.
46. Friedman JM, Liang G, Liu CC, et al. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res 2009; 69: 2623-9.
47. Sasaki D, Imaizumi Y, Hasegawa H, et al. Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. Haematologica 2011; 96: 712-9.
48. Alajez NM, Shi W, Hui AB, et al. Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell Death Dis 2010; 1: e85.
49. Lu J, He ML, Wang L, et al. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 2011; 71: 225-33.
50. Zhang B, Liu XX, He JR, et al. Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis 2011; 32: 2-9.
51. Ciarapica R, Russo G, Verginelli F, et al. Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma. Cell Cycle 2009; 8: 172-5.
52. Bao B, Wang Z, Ali S, et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) 2012; 5: 355-64.
53. Dang X, Ma A, Yang L, et al. MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. Cancer Genet 2012; 205: 113-23.
54. Sander S, Bullinger L, Klapproth K, et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008; 112: 4202-12.
55. Koh CM, Iwata T, Zheng Q, et al. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget 2011; 2: 669-83.
56. Derfoul A, Juan AH, Difilippantonio MJ, et al. Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis 2011; 32: 1607-14.
57. Cao Q, Mani RS, Ateeq B, et al. Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell 2011; 20: 187-99.
58. Bao B, Ali S, Banerjee S, et al. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res 2012; 72: 335-45.
59. Yamagishi M, Nakano K, Miyake A, et al. Polycomb-mediated loss of miR-31 activates NIK-dependent NF-κB pathway in adult T cell leukemia and other cancers. Cancer Cell 2012; 21: 121-35.
60. Zheng F, Liao YJ, Cai MY, et al. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 2012; 61: 278-89.
61. Atkinson SR, Marguerat S, Bähler J,. Exploring long non-coding RNAs through sequencing. Semin Cell Dev Biol 2012; 23: 200-5.
62. Nagano T, Fraser P,. No-nonsense functions for long noncoding RNAs. Cell 2011; 145: 178-81.
63. Bonasio R, Tu S, Reinberg D,. Molecular signals of epigenetic states. Science 2010; 330: 612-16.
64. Gibb EA, Vucic EA, Enfield KS, et al. Human cancer long non-coding RNA transcriptomes. PLoS One 2011; 6: e25915.
65. Guttman M, Donaghey J, Carey BW, et al. lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature 2011; 477: 295-300.
66. Ng SY, Johnson R, Stanton LW,. Human long non-coding RNAs promote pluripotency and neuronal differentiation by association with chromatin modifiers and transcription factors. EMBO J 2011; 31: 522-33.
67. Wu SC, Kallin EM, Zhang Y,. Role of H3K27 methylation in the regulation of lncRNA expression. Cell Res 2010; 20: 1109-16.
68. Carthew RW, Sontheimer EJ,. Origins and Mechanisms of miRNAs and siRNAs. Cell 2009; 136: 642-55.
69. Salmena L, Poliseno L, Tay Y, et al. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell 2011; 146: 353-8.
70. Ørom UA, Shiekhattar R,. Long non-coding RNAs and enhancers. Curr Opin Genet Dev 2011; 21: 194-8.
71. Benetatos L, Voulgaris E, Vartholomatos G,. DLK1-MEG3 imprinted domain microRNAs in cancer biology. Crit Rev Eukaryot Gene Expr 2012; 22: 1-15.
72. Braconi C, Kogure T, Valeri N, et al. MicroRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene 2011; 30: 4750-6.
73. Liu L, Luo GZ, Yang W, et al. Activation of the imprinted Dlk1-Dio3 region correlates with pluripotency levels of mouse stem cells. J Biol Chem 2010; 285: 19483-90.
74. Zhao J, Ohsumi TK, Kung JT, et al. Genome-wide identification of polycomb-associated RNAs by RIP-seq. Mol Cell 2010; 40: 939-53.
75. Jeon Y, Lee JT,. YY1 tethers Xist RNA to the inactive X nucleation center. Cell 2011; 146: 119-33.
76. Li X, Wu Z, Fu X, et al. Long Noncoding RNAs: insights from biological features and functions to diseases. Med Res Rev, in press.
77. Hung T, Chang HY,. Long noncoding RNA in genome regulation: prospects and mechanisms. RNA Biol 2010; 7: 582-5.
78. Spizzo R, Almeida MI, Colombatti A, et al. Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene, in press.
79. Prensner JR, Chinnaiyan AM,. The emergence of lncRNAs in cancer biology. Cancer Discov 2011; 1: 391-407.
80. Tsai MC, Spitale RC, Chang HY,. Long intergenic noncoding RNAs: new links in cancer progression. Cancer Res 2011; 71: 3-7.
81. Huarte M, Rinn JL,. Large non-coding RNAs: missing links in cancer? Hum Mol Genet 2010; 19 (R2): R152-61.
82. Benetatos L, Vartholomatos G, Hatzimichael E,. MEG3 imprinted gene contribution in tumorigenesis. Int J Cancer 2011; 129: 773-9.
83. Hung T, Wang Y, Lin MF, et al. Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. Nat Genet 2011; 43: 621-9.
84. Tsai MC, Manor O, Wan Y, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010; 329: 689-93.
85. Rinn JL, Kertesz M, Wang JK, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007; 129: 1311-23.
86. Kogo R, Shimamura T, Mimori K, et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res 2011; 71: 6320-6.
87. Chu C, Qu K, Zhong FL, et al. Genomic maps of long noncoding RNA occupancy reveal principles of RNA-chromatin interactions. Mol Cell 2011; 44: 667-78.
88. Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010; 464: 1071-6.
89. Kim K, Jutooru I, Chadalapaka G, et al. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene, in press.
90. Yang F, Zhang L, Huo XS, et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology 2011; 54: 1679-89.
91. Prensner JR, Iyer MK, Balbin OA, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 2011; 29: 742-9.
92. Yap KL, Li S, Muñoz-Cabello AM, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 2010; 38: 662-74.
93. Cesana M, Cacchiarelli D, Legnini I, et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 2011; 147: 358-69.